Fig. 1 · Structure

Documents & Downloads

MK-8033

Cat. No. A11489 CAS 1001917-37-8

c-Met inhibitor

MK-8033 is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
Ron IC50 7 nM

MK-8033 Research Summary

This section summarizes 4 in vitro studies of MK-8033 from 3 published references. In vitro models include WT uveal melanoma cells; a panel of OVCA cell lines.

MK-8033 In Vitro Studies

MK-8033 treatment reduced MET phosphorylation in wild-type uveal melanoma cells and GNAQ mutant cells by relatively similar proportions compared with baseline. Incubation with MK-8033 produced strong antiproliferative effects against a panel of OVCA cell lines. In a human cathepsin L assay, the reported IC50 was <0.5 nM. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Reduced MET phosphorylation in wild-type uveal melanoma cells

Cell-based study · WT uveal melanoma cells (MEL290) [1]

MK-8033 treatment reduced MET phosphorylation in WT uveal melanoma cells (MEL290) relative to baseline.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MET phosphorylationReported result Cells were treated with MK-8033 at either 0, 1 or 2.5 µM concentrations. METi treatment reduced MET phosphorylation in both GNAQ mutant or wild-type cells by a relatively similar proportion, relative to baseline MET phosphorylation levels.[1]

Literature-Reported Treatment Conditions

Treatment concentration
0, 1 and 2.5 µM
Vehicle
dimethyl sulfoxide (DMSO)
Reported limits
Not stated in the sentences used: route, schedule.
Methods and source locations

Compound reported in the paper: MK-8033

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Reagents (S4); Results > Effect of MEKi and/or METi Treatment on MET and Erk1/2 Phosphorylation in Uveal Melanoma Cells (S51, S52); Figure 2 legend (S84)

MET phosphorylation: MET phosphorylation; comparator: baseline MET phosphorylation levels — Results > Effect of MEKi and/or METi Treatment on MET and Erk1/2 Phosphorylation in Uveal Melanoma Cells (S51, S52); Figure 2 legend (S84)

Antiproliferative effects in OVCA cell lines

Cell-based study · a panel of OVCA cell lines [2]

Incubation of a panel of OVCA cell lines with MK-8033 produced strong antiproliferative effects.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
percent OVCA cell viabilityReported result 72-h incubation with MK8033: strong anti-proliferative effects against a panel of OVCA cell lines.[2]

Literature-Reported Treatment Conditions

Exposure duration
72-h incubation
Method
incubation with MK8033
Reported limits
Not stated in the sentences used: dose, vehicle.
Methods and source locations

Compound reported in the paper: MK-8033

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Cell viability assays (S25); Results > Inhibition of HGF/c-Met signaling has in vitro anti-proliferative effects on OVCA cells and synergizes with combination carboplatin plus paclitaxel (S45); Figure 1 legend (S51)

percent OVCA cell viability: percent OVCA cell viability; comparator: untreated cells — Results > Inhibition of HGF/c-Met signaling has in vitro anti-proliferative effects on OVCA cells and synergizes with combination carboplatin plus paclitaxel (S45); Figure 1 legend (S51)

Human cathepsin L inhibition

Cell-based study · human cathepsin L [3]

Against human cathepsin L, the compound had an IC50 of <0.5 nM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cathepsin L IC50 (nM)IC50 <0.5 nM[3]

Literature-Reported Treatment Conditions

Reported limits
Not stated in the sentences used: dose, route, schedule, vehicle, control.
Methods and source locations

Compound reported in the paper: MK-8033; Compound label in the paper: CPD 11R

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > SARS-CoV-2 3CLpro and human cathepsin L biochemical assays (S1); Table 1 (T1.r1, T1.r2)

Cathepsin L IC50 (nM): Cathepsin L IC50 (nM) — Table 1 (T1.r2)

Reduced MET phosphorylation in GNAQ mutant cells

Cell-based study · GNAQ mutant cells (MEL202) [1]

MK-8033 treatment reduced MET phosphorylation in GNAQ mutant cells (MEL202) relative to baseline, by a relatively similar proportion to that observed in wild-type cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MET phosphorylationReported result Cells were treated with MK-8033 at either 0, 1 or 2.5 µM concentrations. METi treatment reduced MET phosphorylation in both GNAQ mutant or wild-type cells by a relatively similar proportion, relative to baseline MET phosphorylation levels.[1]

Literature-Reported Treatment Conditions

Treatment concentration
0, 1 and 2.5 µM
Vehicle
dimethyl sulfoxide (DMSO)
Reported limits
Not stated in the sentences used: route, schedule.
Methods and source locations

Compound reported in the paper: MK-8033

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Reagents (S4); Results > Effect of MEKi and/or METi Treatment on MET and Erk1/2 Phosphorylation in Uveal Melanoma Cells (S51, S52); Figure 2 legend (S84)

MET phosphorylation: MET phosphorylation; comparator: baseline MET phosphorylation levels — Results > Effect of MEKi and/or METi Treatment on MET and Erk1/2 Phosphorylation in Uveal Melanoma Cells (S51, S52); Figure 2 legend (S84)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1001917-37-8
Applications c-Met inhibitor
Formula C25H21N5O3S
Molecular Weight 471.53
SMILES
CN1C=C(C=N1)C2=CN=C3C=CC4=C(C=C(C=C4)CS(=O)(=O)NCC5=CC=CC=N5)C(=O)C3=C2

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

MK-8033 Research References

  1. [1] Chattopadhyay C, Grimm EA, Woodman SE. Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration. PLoS One (2014). PMID: 24551032 DOI: 10.1371/journal.pone.0083957 Source material
  2. [2] Marchion DC, Bicaku E, Xiong Y, et al. A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep (2013). PMID: 23467907 DOI: 10.3892/or.2013.2329 Source material
  3. [3] Vandyck K, Abdelnabi R, Gupta K, et al. ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model. Biochem Biophys Res Commun (2021). PMID: 33813272 DOI: 10.1016/j.bbrc.2021.03.096 Source material

Added to your cart

View Cart Checkout
Loading...